NCT01755975

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested. This study will test a new combination of two drugs that are already approved by the Food and Drug Administration for treatment of certain kinds of blood cancers. These drugs are romidepsin and lenalidomide. Both these drugs by themselves have been used to treat lymphoma or multiple myeloma. However, while these drugs are routinely used alone, this is the first time they will be tested together. The mechanism of action of both drugs is not well understood but both have been shown to to be effective by themselves in lymphoma and multiple myeloma.

Conditions

• Multiple Myeloma
• Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	Romidepsin	Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
DRUG	Lenalidomide	Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.

Timeline

• Start date: 2012-12-01
• Primary completion: 2023-10-01
• Completion: 2023-10-01
• First posted: 2012-12-24
• Last updated: 2024-11-07
• Results posted: 2024-11-07

Locations

7 sites across 1 country: United States